enGene Therapeutics (ENGN) Other financing activities (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Other financing activities of -$126.0 million for Q2 2026, down 63401.51% year-over-year from N/an in Q2 2025, and down 199.78% quarter-over-quarter from $126.2 million in Q1 2026.
enGene Therapeutics (ENGN) Other financing activities (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Other financing activities for 4 consecutive years, with -$126.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other financing activities fell 63401.51% year-over-year to -$126.0 million; the TTM figure through Apr 2026 stood at $2.3 million (down 96.18% YoY), while the FY2025 annual figure was $2.2 million, down 99.15% from the prior year.
- Other financing activities slipped to -$126.0 million in Q2 2026 per ENGN's latest filing, from $126.2 million in the prior quarter.
- Across five years, Other financing activities topped out at $126.2 million in Q1 2026 and bottomed at -$126.0 million in Q2 2026.
- Historically, Other financing activities has averaged $14.9 million across 4 years, with a median of $1.1 million in 2025.
- On a YoY basis, Other financing activities climbed as much as 12624900.0% in 2026 and fell as far as 63401.51% in 2026.
- enGene Therapeutics' Other financing activities stood at $56.9 million in 2023, then increased by 5.76% to $60.1 million in 2024, then plunged by 96.69% to $2.0 million in 2025, then plunged by 6426.97% to -$126.0 million in 2026.
- Business Quant data shows ENGN's Other financing activities at -$126.0 million in Q2 2026, $126.2 million in Q1 2026, and $2.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -125.97 Mn |
| Apr 30, 2026 | -125.97 Mn |
| Jan 31, 2026 | 126.25 Mn |
| Jan 31, 2026 | 126.25 Mn |
| Oct 31, 2025 | 1.99 Mn |
| Oct 31, 2025 | 1.99 Mn |
| Jul 31, 2025 | 32,000.00 |
| Jul 31, 2025 | 32,000.00 |
| Apr 30, 2025 | 199,000.00 |
| Apr 30, 2025 | 199,000.00 |
| Jan 31, 2025 | 1,000.00 |
| Jan 31, 2025 | 1,000.00 |
| Oct 31, 2024 | 60.15 Mn |
| Oct 31, 2024 | 60.15 Mn |
| Oct 31, 2023 | 56.88 Mn |
| Oct 31, 2023 | 56.88 Mn |